WAVE Life Sciences Garners $66,000,000 Series B Funding

  • Feed Type
  • Date
    8/18/2015
  • Company Name
    WAVE Life Sciences
  • Mailing Address
    419 Western Avenue Boston, MA 02135 USA
  • Company Description
    WaVe Life Sciences is leading a revolution in nucleic acid therapeutics and was founded on the core principle that medicines should possess precisely controlled molecular structures. We and our strategic partners are advancing a portfolio of stereopure drug candidates that target underlying biology across a wide range of human diseases.
  • Website
    http://www.wavelifesciences.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $66,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    WAVE expects to use the proceeds from the Series B financing to continue to evolve its chemistry platform and advance a broad pipeline of stereopure nucleic acid therapeutics, including candidates for Huntington’s disease and Duchenne muscular dystrophy, across a breadth of oligonucleotide modalities, including RNAi, antisense and exon-skipping, among others. The company plans to file its first INDs by the end of 2016.
  • M&A Terms
  • Venture Investor
    Foresite Capital
  • Venture Investor
    Fidelity Management & Research Company
  • Venture Investor
    New Leaf Venture Partners
  • Venture Investor
    Redmile Group
  • Venture Investor
    Jennison Associates
  • Venture Investor
    Cormorant Asset Management
  • Venture Investor
    RA Capital

Trending on Xconomy